title: Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation.
authors.forename: Babak
authors.initials: B
authors.lastname: Yazdani-Biuki
authors.forename: Thomas
authors.initials: T
authors.lastname: Mueller
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Brezinschek
authors.forename: Josef
authors.initials: J
authors.lastname: Hermann
authors.forename: Winfried
authors.initials: W
authors.lastname: Graninger
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Wascher
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab